# Risk: __Variation in protection against re-infections__ (PBN__Risk_1914)

## Property: has_RiskISO_Impact

* [Health and care](../RiskISO/PBN__RiskISO_Purpose_0)

## Property: has_RiskTechnology

* [research and data analysis technologies](../Technology/PBN__Technology_1312)

## Property: has_RiskSubject

* [re-infected individuals](../Stakeholder/PBN__Stakeholder_1296)
* [researchers](../Stakeholder/PBN__Stakeholder_2)

## Property: has_RiskType

* [medical](../RiskType/PBN__RiskType_15)

## Property: has_RiskISO_Purpose

* [Health and care](../RiskISO/PBN__RiskISO_Impact_3)

## Property: has_RiskOwner

* [healthcare providers](../Stakeholder/PBN__Stakeholder_121)
* [researchers](../Stakeholder/PBN__Stakeholder_2)

## Property: has_RiskMitigation

* [Evaluate the difference in efficacy between symptomatic and asymptomatic individuals.](../RiskMitigation/PBN__RiskMitigation_2516)

## Property: has_RiskName

Uncertainty in the efficacy of protection against re-infections in symptomatic and asymptomatic individuals.

## Property: has_RiskDescription

Potential difference in protection against re-infections based on symptomatic status in initial infection.

## Property: has_RiskSource

* [pilz_contributions_2022](../Article/PBN__Article_245)

## Property: has_RiskGBN

* [Yes](../RiskGBN/PBN__RiskGBN_1)

## Property: has_RiskHealth

* [physical](../RiskHealth/PBN__RiskHealth_0)

